FAQ on Nutriband Inc. (NASDAQ: NTRB) and Its AVERSA™ Abuse-Deterrent Technology

What is Nutriband Inc. known for?

Nutriband Inc. is known for developing transdermal pharmaceutical products, notably its AVERSA™ abuse-deterrent technology aimed at preventing the abuse of drugs with abuse potential like fentanyl.

What is AVERSA™ technology?

AVERSA™ technology is an abuse-deterrent innovation by Nutriband that can be incorporated into any transdermal patch to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

Why is AVERSA™ technology significant?

AVERSA™ technology is significant because it improves the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while ensuring these drugs remain accessible to patients who need them.

Where is AVERSA™ technology patented?

AVERSA™ technology is patented in the United States, Europe, Japan, Korea, Russia, Canada, Mexico, Australia, China, and has recent extensions into Macao.

How does Nutriband’s business model work?

Nutriband’s business model involves applying its transdermal technology to existing FDA-approved drugs to improve safety, efficacy, and patient comfort, qualifying for a regulatory pathway that reduces the number of required clinical trials for new drug approval.

Where can I find more information about Nutriband Inc.?

More information about Nutriband Inc. can be found on their website at www.Nutriband.com or in the company’s newsroom at https://ibn.fm/NTRB.

What is the latest development regarding Nutriband Inc.?

The latest development is Nutriband’s AVERSA™ technology being featured in an article highlighting its potential to improve the safety of transdermal drugs, with details available at https://ibn.fm/aeURJ.

Who is behind the coverage of Nutriband Inc.?

The coverage is provided by BioMedWire, a specialized communications platform focusing on Biotechnology, Biomedical Sciences, and Life Sciences sectors, part of the InvestorBrandNetwork.